Skip to content

Core Laboratories CLB Production Enhancement — Goodwill

Similar metrics at other companies

Flowco Holdings Inc. logo
FLOCProduction Solutions — Goodwill Gross
$244.3M+29.4%
Flowco Holdings Inc. logo
FLOCProduction Solutions — Goodwill
$238.92M+30.3%
Flowco Holdings Inc. logo
FLOCProduction Solutions — Goodwill Impaired Accumulated Impairment Loss
$5.37M0.0%
Flowco Holdings Inc. logo
FLOCProduction Solutions — Goodwill Impairment Accumulated Impairement Losses
$0
Flowco Holdings Inc. logo
FLOCProduction Solutions — Goodwill Gross Impairment Loss
$0
Voya Financial logo
VOYAInvestment Management Segment — Goodwill
$286M0.0%

Other financials

Income statement

See full
Revenue$121.8M-1.4%
Operating income$1.9M-57.3%
Net income-$789.0K-412%
EPS (diluted)-$0.02

Balance sheet

See full
Cash & equivalents$22.8M+3.2%
Total debt$167.8M-6.8%
Total equity$268.9M+6.1%
Total assets$587.7M+0.3%

Cash flow

See full
Operating cash flow$4.0M-40.5%
CapEx$3.4M+23.8%
Free cash flow$517.0K-86.7%

Valuation

See full
Market cap$503.38M-13.5%
Enterprise value$648.4M-12.3%
P/E17.3×-3.4×
P/S-0.2×

Profitability

See full
Operating margin10.3%-0.2pp
Net margin5.5%+0.1pp
FCF margin4.3%-4.6pp

Returns & leverage

See full
Return on equity11.1%-0.4pp
Debt / equity0.6×-0.1×
Current ratio-0.2×

Where this comes from

Reported directly by Core Laboratories in its filing.

Tagged under the XBRL concept us-gaap:Goodwill.

The official record: Core Laboratories’s 10-K, filed March 21, 2026, on SEC EDGAR. View the filing →

Ask your AI about Core Laboratories's production enhancement — goodwill.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Core Laboratories's production enhancement — goodwill?
Core Laboratories (CLB) reported production enhancement — goodwill of $0 in Q4 2025.
What does production enhancement — goodwill mean?
This metric represents the total carrying value of goodwill allocated to the Production Enhancement business segment. It reflects the excess of the purchase price over the fair value of net identifiable assets acquired in historical business combinations specific to this segment. Investors use this to assess the historical investment intensity and potential impairment risk associated with the segment's growth strategy.